Valuentum Exclusive Analysis for the Discerning Investor

Symbol Keyword

Mar 21, 2024

Pfizer 6% Dividend Yield Speaks of Considerable Risk, Free Cash Flow Coming Up Short
Image: Pfizer’s shares have been under considerable pressure the past few years. Though we are positive on Pfizer’s turnaround, its Dividend Cushion ratio of 0.3 is not to be taken lightly (any ratio below 1 indicates heightened risk of a dividend cut). Income-oriented investors seeking a turnaround story may be interested in Pfizer, but we’re staying on the sidelines. We’ll continue to monitor developments at the pharma giant, especially as patents on several of its major drugs approach expiration. Shares yield ~6% at the time of this writing.

Feb 25, 2024

We Remain Bullish; Is This 1995 – The Beginning of a Huge Stock Market Run?
Image: Large cap growth stocks have trounced the performance of the S&P 500, REITs, and bonds since the beginning of 2023. We expect continued outperformance in this area of the market. We’re now roughly four years past the depths of the COVID-19 meltdown, where equities collapsed in February and March of 2020. As the markets began to recover through 2020, our long-term conviction in equities only grew stronger. We think the biggest risk for long-term investors remains staying out of the market on the basis of what could be considered stretched valuation multiples. As we outlined heavily in the book Value Trap, valuation multiples hardly tell the complete story about a company and often omit key long-term earnings growth, cash flow dynamics, and balance sheet health considerations. We remain bullish on equities for the long haul, and we think the next couple years will be incredibly strong. Our best ideas can be found in the Best Ideas Newsletter portfolio, Dividend Growth Newsletter portfolio, High Yield Dividend Newsletter portfolio, ESG Newsletter portfolio, and via the Exclusive publication as well as options idea generation.

Feb 11, 2024

Eli Lilly’s Shares Have More Than Doubled During the Past 52 Weeks
Image: Eli Lilly’s shares have been on a tear these past few years. On February 6, Eli Lilly reported excellent fourth-quarter results that showed revenue and non-GAAP earnings per share coming in better than expectations. The company’s fourth-quarter results were bolstered by sales of diabetes and weight-loss drug Mounjaro, which saw sales in the quarter leap to ~$2.2 billion from ~$279 million in the year ago period. We continue to be in awe of the sales momentum behind GLP-1 receptor agonists, and the opportunity continues to be robust, despite already rapid sales acceleration. Though Eli Lilly trades at a premium to the high end of our fair value estimate range, we may be low in our expectations of the company’s ability to tap this lucrative market in the longer run, and shares may still be attractive to the risk-seeking aggressive growth investor.

Dec 23, 2023

12 Reasons to Stay Aggressive in 2024
From outperforming simulated newsletter portfolios to fantastic success rates in the Exclusive publication to option ideas and great income-oriented ideas and beyond, we continue to deliver across our simulated newsletter suite as our latest video outlines. It’s hard to know exactly what 2024 will bring in terms of a market return, but the internals of the stock market and the U.S. economy look great to us. The new bull market we’re in could last for years, and as a result, we are staying aggressive with many of our new ideas as we look to benefit from these favorable trends.

Sep 20, 2023

ICYMI: Questions for Valuentum’s Brian Nelson
Valuentum's President Brian Nelson, CFA, answers your questions.

Dec 27, 2022

Exclusive Call: What To Expect From Valuentum in 2023
Video: 2022 was a successful year by almost every measure from the simulated Best Ideas Newsletter portfolio and simulated Dividend Growth Newsletter portfolio to the simulated High Yield Dividend Newsletter portfolio and Exclusive publication and beyond. There were some disappointments in 2022, of course, but the year showed the value of a Valuentum membership. Join President of Investment Research Brian Nelson on this year's Exclusive conference call to learn what to expect from Valuentum in 2023. Cheers!

Nov 30, 2022

Great Year for (Our) High Yield Dividend Ideas! Inquire about the High Yield Dividend Newsletter!
Image: The year-to-date simulated estimated performance of the High Yield Dividend Newsletter portfolio, which continues to hold up well during 2022, while offering an attractive forward estimated dividend yield. Simulated estimated performance is calculated by Valuentum and has not been externally audited. Inquire about the High Yield Dividend Newsletter. The next edition will be released December 1, 2022. Based on our estimates, the simulated High Yield Dividend Newsletter portfolio is down ~4.4% on a price-only basis so far in 2022 on an interim basis, using data from the trading session November 29 (retrieved from Seeking Alpha). By comparison, according to data from Morningstar, the Vanguard 60/40 stock/bond portfolio (VBIAX) is down more than 15% so far this year (on a price-only basis), the Vanguard Real Estate ETF (VNQ) is down 26% year-to-date (on a price-only basis), while the iShares Mortgage Real Estate Capped ETF (REM) is down ~30% on a year-to-date basis. Each simulated newsletter portfolio at Valuentum targets a different strategy, whether long-term capital appreciation, dividend growth, income/high yield, and the like. Generally, for the simulated Best Ideas Newsletter portfolio, it targets long-term capital appreciation potential (not in one year or a couple years, but in the long run). During the past five years...an ETF that tracks the area of large cap growth is up more than 70%, while an ETF that tracks the area of dividend growth has advanced ~40%, an ETF that tracks small cap value is up ~17% during the past five years, while an ETF that tracks the area of the highest-yielding S&P 500 companies is up just 12% -- according to data from Morningstar. REITs, as measured by the VNQ, are up just 3% over the past five years. We nailed the call on the drawdown in the 60/40 stock/bond portfolio this year, and readers should continue to question the merits of modern portfolio theory, not merely state that now the 60/40 stock/bond is cheap (after the huge decline)! It's extremely important to continue to test whether something makes sense or not. If interest rates continue to rise, we think bond prices will continue to face pressure. Sometimes, a few of our best ideas don't work out (as in any year), but that's why we use the simulated (and diversified) Best Ideas Newsletter portfolio to measure the success of the VBI. We're not a quant shop. We believe in the qualitative overlay. For example, there are highly-rated ideas that don't make the cut for the simulated Best Ideas Newsletter portfolio and there are low-rated ideas that find their way into the newsletter portfolio because they add a diversification benefit. Given the massive up years in the broader markets in 2019, 2020 and 2021, with the simulated Best Ideas Newsletter portfolio estimated to be down in the low-double-digits so far this year (approximately ~10%-12%, by our latest tally) -- and this estimate includes the missteps in Meta Platforms (META), PayPal (PYPL), and Disney (DIS) -- this is actually pretty awesome, in our view -- especially considering all that went wrong in other areas such as crypto, REITs, mortgage REITs, disruptive innovation stocks, Chinese equities, and the list goes on and on. A low double-digit estimated percentage decline, as that "experienced" in the simulated Best Ideas Newsletter portfolio so far in 2022 after huge up years, can be viewed as just part of a long-term journey that targets capital appreciation. For context, Berkshire Hathaway's stock price was nearly halved in 1974. It's okay to time the markets a bit as we did last August, but staying engaged with investing over the long haul is a key part of the recipe for success, as it was for Berkshire investors. For readers seeking income and high yield dividend ideas, please consider subscribing to our High Yield Dividend Newsletter. 2022 hasn't been an up year for a lot of investors, but it shouldn't have been a disaster either, and we've done a really great job avoiding the worst areas. We're interested in hearing how you are using our service, so that we can continue to get better. All told, we're excited about 2023, and we hope you are too!

Nov 28, 2022

2022 Showcased the Value of a Valuentum Membership
In bull markets, almost everyone is a winner. But 2022 was different. This year was a big test for Valuentum, and we passed with flying colors. We delivered across the board during the year from ideas in the Exclusive publication and the efficacy of the dividend growth methodology to the resilience of high yield ideas and simulated Best Ideas Newsletter portfolio relative performance--despite setbacks from Meta Platforms, PayPal, and beyond. Tune in to the latest video installment from Valuentum. Thanks for listening!

Nov 10, 2022

Market Whipsaw: Crypto Collapse and a Lower-than-Expected Inflation Print
Image: Uncertainty in the cryptocurrency markets has surged with concerns over the liquidity of a key exchange. Investors are weighing the spillover effects of crypto with the view that the pace of inflation may have peaked. The U.S. equity market continues to be highly volatile as it whipsaws between concerns over the health and sustainability of cryptocurrency and optimism over lower-than-feared inflation readings. We maintain our bearish/defensive stance on equities, but at the same time, we continue to be “fully-invested” across the simulated newsletter portfolios in part because we don’t want to miss out on days like today, November 10, when the markets are soaring ~2.5%-5.5% depending on which index you are monitoring. We’re also not ruling out a Santa Claus rally through the end of the year. Merry Dow Jones, as they say!

Nov 3, 2022

Lumen’s Dividend Cut Highlights Effectiveness of Valuentum’s Dividend Methodology and Uniqueness of Dividend Cushion Ratio
A lot of times investors only focus on the dividend payout ratio – dividends paid per share divided by earnings per share – or free cash flow coverage of the dividend, but the balance sheet is so very important to the sustainability of the dividend, too – something that the Dividend Cushion ratio embraces but other dividend health metrics do not. For example, Lumen’s dividend payout ratio was 50% ($0.75 in dividends dividend by $1.50 in earnings per share during the first three quarters of the year), and its free cash flow was enough to cover its cash dividends paid during the first nine months of 2022, too. However, the company held a massive ~$25 billion net debt position at the end of the quarter, which pushed its Dividend Cushion ratio deep into negative territory, raising a huge red flag with respect to the sustainability of the payout. Ignoring the balance sheet both with respect to intrinsic value and dividend analysis could be a recipe for disaster.